Bank of America Corp DE Decreases Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Bank of America Corp DE lowered its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 80.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 120,977 shares of the company's stock after selling 506,719 shares during the period. Bank of America Corp DE owned approximately 0.20% of Pliant Therapeutics worth $1,593,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of PLRX. Swiss National Bank grew its position in shares of Pliant Therapeutics by 1.6% during the 4th quarter. Swiss National Bank now owns 95,700 shares of the company's stock worth $1,260,000 after buying an additional 1,500 shares in the last quarter. Atria Investments Inc grew its stake in Pliant Therapeutics by 18.1% during the 4th quarter. Atria Investments Inc now owns 11,821 shares of the company's stock worth $156,000 after buying an additional 1,812 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Pliant Therapeutics by 0.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 459,384 shares of the company's stock valued at $6,050,000 after acquiring an additional 2,721 shares in the last quarter. Rice Hall James & Associates LLC raised its holdings in shares of Pliant Therapeutics by 2.1% in the fourth quarter. Rice Hall James & Associates LLC now owns 160,522 shares of the company's stock worth $2,114,000 after buying an additional 3,305 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its position in Pliant Therapeutics by 11.9% during the 4th quarter. MetLife Investment Management LLC now owns 36,788 shares of the company's stock worth $484,000 after acquiring an additional 3,925 shares during the period. Hedge funds and other institutional investors own 97.30% of the company's stock.

Wall Street Analysts Forecast Growth

PLRX has been the topic of several research reports. Needham & Company LLC reiterated a "hold" rating and issued a $10.00 price target on shares of Pliant Therapeutics in a report on Tuesday, March 4th. Oppenheimer reiterated a "market perform" rating on shares of Pliant Therapeutics in a research note on Monday, February 10th. Leerink Partnrs downgraded shares of Pliant Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 3rd. Royal Bank of Canada cut their price target on Pliant Therapeutics from $4.00 to $3.00 and set a "sector perform" rating on the stock in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company reduced their price objective on Pliant Therapeutics from $4.00 to $3.00 and set an "equal weight" rating for the company in a research note on Tuesday, March 4th. Twelve analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $13.31.

Pliant Therapeutics Price Performance

Shares of PLRX stock traded up $0.02 during mid-day trading on Friday, hitting $1.63. 956,765 shares of the stock were exchanged, compared to its average volume of 1,117,563. Pliant Therapeutics, Inc. has a 52-week low of $1.10 and a 52-week high of $16.10. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The company has a market cap of $100.06 million, a PE ratio of -0.49 and a beta of 1.35. The firm has a fifty day moving average of $1.42 and a 200 day moving average of $6.22.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.99) by $0.17. Research analysts anticipate that Pliant Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.